

Natco Pharma Limited

Regd. Off.: 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.
Telangana, INDIA. Tel: +91 40 23547532, Fax: +91 40 23548243
CIN: L24230TG1981PLC003201, www.natcopharma.co.in

April 4, 2018

Corporate Relationship Department

M/s. BSE Ltd Dalal Street, Fort Mumbai- 400 001 Manager - Listing

M/s. National Stock Exchange of India Ltd "Exchange Plaza", Bandra – Kurla Complex

Bandra (E) Mumbai -400 051

Scrip Code: **524816** Scrip Code: **NATCOPHARM**

Dear Sir

Please find enclosed herewith the Press Release for your information.

Thanking you

Yours faithfully For NATCO Pharma Limited

MANdrayana

M Adinarayana

Company Secretary &

Vice President (Legal & Corp Affairs)



Natco Pharma Limited

Regd. Off.: 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.
Telangana, INDIA. Tel: +91 40 23547532, Fax: +91 40 23548243
CIN: L24230TG1981PLC003201, www.natcopharma.co.in

Ref: PR/ 1 /2018-2019

Press Release

NATCO launches 1st generic version of Oral tablets for Multiple Sclerosis in INDIA

Hyderabad, India, April 4th, 2018

Natco Pharma Limited (NSE: NATCOPHARM; BSE: 524816) announced today that it is the first company in India to launch a generic version of Teriflunomide, for the treatment of Relapsing and Remitting forms of Multiple Sclerosis (RRMS), under its brand DENOPSY. This is the first oral medicine for RRMS being offered in India at two different strengths- 14 mg & 7 mg tablets. Teriflunomide is sold by Sanofi-Genzyme under brand name of AUBAGIO®, in the USA market.

DENOPSY is priced attractively & much lower than other alternate options in India. As per WHO 2013 estimates, the number of patients suffering from Multiple Sclerosis in India is 5-20 per 1 lakh population.

Forwarded for favour of publication For NATCO Pharma Limited

M Adinarayana

Company Secretary &

Vice President (Legal & Corp Affairs)